Redefining Lupus Clinical Trials Amid COVID-19 and Beyond

Ensuring the clinical trial process is accommodating for participants has always been the goal. However, COVID-19 has forced industry, research organizations, doctors, and patients to think twice about the process and its impact on high-risk populations including people with lupus who are immuno-compromised. Albert T. Roy, Executive Director, Lupus Therapeutics, the clinical trial innovation division of the Lupus Research Alliance (LRA), sits down with an expert panel to discuss clinical trial innovation and why COVID-19 may be the spark needed to empower patients and drive clinical trial innovation. Panelists:

  • Shanelle Gabriel – Singer, HBO Def Poet, Lyricist, Advocate for Lupus Awareness
  • Molly McCabe – Co-Founder of the former Molly’s Fund Fighting Lupus and Member, LRA Board of Directors
  • David R. Karp, MD, PhD Chief, Division of Rheumatic Diseases, UT Southwestern Medical Center, President-Elect, American College of Rheumatology
  • Craig Lipset – Advisor and Founder, Clinical Innovation Partners
  • Ajay Nirula, MD, PhD – Vice President, Immunology, Lilly Biotechnology & Research Laboratories
  • Shalabh Singhal, MD – Development Program Lead, Immunology & Fibrosis, Bristol Myers Squibb

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up